The tweet was deleted by the author.
But we saved everything 🙂.
Michael Taylor, co-founder / portfolio manager at Agora Trading, highlights that AQRT has a planned Phase 2 go/nogo study for Vitiligo, an autoimmune pigmenting disorder, set for 4Q26.
Taylor notes that this represents a $1 billion market and could double AQRT’s total addressable market compared to ZORYVE topical, with the market currently not pricing in this potential.
View post on X Loading...
Taylor previously identified FJET as a little-known bear trade opportunity earlier this year. He also projected that the U.S. Federal Reserve could enact multiple interest rate cuts in 2027, citing factors like lower energy costs in a separate report on Fed policy expectations. These past assessments reflect Taylor’s ongoing focus on emerging trends and under-recognized market developments.